- Q1 2024 Valneva SE Earnings Call TranscriptMay 07, 2024€3.41 (-1.16%)Earnings
- Full Year 2023 Valneva SE Earnings Call TranscriptMar 20, 2024€3.37 (-10.66%)Earnings
- Valneva SE Analyst Call TranscriptNov 13, 2023
- Q3 2023 Valneva SE Earnings Call TranscriptNov 09, 2023€6.18 (+0.62%)Earnings
- Half Year 2023 Valneva SE Earnings Call TranscriptSep 21, 2023€6.04 (-4.16%)Earnings
- Valneva SE at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Valneva SE Earnings Call TranscriptMay 04, 2023€5.31 (+26.70%)Earnings
- Full Year 2022 Valneva SE Earnings Call TranscriptMar 23, 2023€4.82 (-1.63%)Earnings
- Valneva SE Corporate Analyst Meeting TranscriptDec 06, 2022
- Q3 2022 Valneva SE Earnings Call TranscriptNov 10, 2022€7 (+4.60%)Earnings
- Half Year 2022 Valneva SE Earnings Call TranscriptAug 11, 2022€9.96 (-5.14%)Earnings
- Valneva SE at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Valneva SE COVID-19 Vaccine Purchase Agreement Update TranscriptMay 16, 2022
- Q1 2022 Valneva SE Earnings Call TranscriptMay 05, 2022€11.86 (+0.13%)Earnings
- Full Year 2021 Valneva SE Earnings Call TranscriptMar 24, 2022€17.35 (+1.17%)Earnings
- Valneva SE - Special Call TranscriptOct 18, 2021
- Half Year 2021 Valneva SE Earnings Call TranscriptAug 10, 2021€3.1Earnings
- Valneva SE Annual Shareholders Meeting TranscriptJun 23, 2021
- Q1 2021 Valneva SE Earnings Call TranscriptMay 20, 2021€3.1Earnings
- Full Year 2020 Valneva SE Earnings Call TranscriptFeb 25, 2021€3.1Earnings
- Q3 2020 Valneva SE Earnings Call TranscriptNov 03, 2020€3.1Earnings
- Half Year 2020 Valneva SE Earnings Call TranscriptAug 04, 2020€3.1Earnings
- Q1 2020 Valneva SE Earnings Call TranscriptMay 07, 2020€3.1Earnings
- Full Year 2019 Valneva SE Earnings Call TranscriptFeb 27, 2020€3.1Earnings
- Nine Months 2019 Valneva SE Earnings Call TranscriptOct 31, 2019€3.1Earnings
- Half Year 2019 Valneva SE Earnings Call TranscriptAug 01, 2019€3.1Earnings
- Valneva SE R&D Investor Day Presentation TranscriptJul 09, 2019
- Valneva SE to Announce Agreement with GlaxoSmithKline PLC to End Strategic Alliance Agreement Call TranscriptJun 21, 2019
- Q1 2019 Valneva SE Earnings Call TranscriptMay 02, 2019€3.1Earnings
- Full Year 2018 Valneva SE Earnings Call TranscriptFeb 21, 2019€3.1Earnings
Full Year 2020 Valneva SE Earnings Call Transcript
Good day, and welcome to Valneva's business update and unaudited full year 2020 financial results. Before we go into the update, I would like to reiterate what I said a couple of times at different occasions. We are proud and grateful to have insured business continuity and employee welfare during the turbulent and transformational year 2020, which is certainly one of the biggest achievements during this time. We have reported excellent progress on our clinical programs in 2020. We reported positive Phase II data on our Lyme disease vaccine and entered into the collaboration with Pfizer, which is progressing in an excellent way. And our teams have worked very hard to accelerate its -- our chikungunya program, which is now the only vaccine candidate in Phase III.
As David will report in more detail, we ended the year with full year cash and cash equivalents of more than EUR 200 million underlying a very strong balance sheet performance in 2020. And this, despite of the fact that along with the rest of the global
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)